Cathie Wood Loads Up Over $6.7M In Adobe Stock As It Tumbles 27% In A Month Over Figma Deal
Cathie Wood-led ARK Investment Management bought over 23,000 shares of software maker Adobe Inc (NASDAQ: ADBE) through the
Nurix Therapeutics Q3 EPS $(0.90) Beats $(0.98) Estimate, Sales $10.79M Miss $12.08M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.98) by 8.16 percent. This is a 38.46 percent decrease over losses of $(0.65) per share from
Tesla, Twitter And 76 Biggest Movers From Friday
Gainers
Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale.
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Lowers Price Target to $54
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $60 to $54.
Why Nurix Therapeutics Shares Are Rising Today
Nurix Therapeutics Inc (NASDAQ: NRIX) shares are trading higher by 13.25% to $17.52 Friday afternoon after the company announced a registered direct offering for total gross proceeds of approximately $40 million.
Nurix Therapeutics’s Return On Capital Employed Insights
Benzinga Pro data, Nurix Therapeutics (NASDAQ:NRIX) reported Q2 sales of $11.43 million. Earnings fell to a loss of $45.40 million, resulting in a 6.74% decrease from last quarter.
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Nurix Therapeutics Announces $40M Registered Direct Offering
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two
Nurix Therapeutics Q2 EPS $(1.01) Down From $(0.60) YoY
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(1.01) per share. This is a 68.33 percent decrease over losses of $(0.60) per share from the same period last year.